Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ASKB589 in advanced or metastatic solid tumors
CTR20202121Phase 2Completed
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ASKB589 in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic cancer (PC), sponsored by Aosaikang Biotherapeutics. Started Jan 2021; status: completed.
02
Drugs
ASKB589
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20202121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202121.